4Gover AU. Impact of the antibiotic dosage schedule on efficacy in experiment softt tissue infection[J]. Scan J Infect Dis,1990,74. (suppl):147.
5James JK, Palmer SM, Levin DP, et al. Comparison if convientional dosing verse continuous-infusion vaneomycin therapy for patients with suspected or documented gram-positive infections [ J]. Antimicobial Agents Chemother,1996,40 : 696.
6Tumidge JD, Gudmundsson S, Vogelman B, et al. The postantibiotic effect of antifungal agents against common pathogenic yeasts[J]. Journal of Antimicobial Chemother, 1994,34 : 83.
7Meibohm B, Derendorf H. Basic concepts of pharmacokinetic/phamacodynamic(PK/PD) modeling[J], Int J Clinical Phamaco Therapeutics. 1997,35(10):401.
8Vogelrnan B, Gudmundsson S, Leggett J, et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model[J]. J Infect Dis, 1988,158:831-847.
9Craig WA. Antimicrobial resistance issues of the future[J]. Diagn Microbiol Infect Dis, 1996,25:213-217.
10Tomqvist IO, Holm SE, Cars O. Phamacodynamic effects of Stabinhibitory antibiotic concentrations[J]. Scand J Infent Dis, 1991(Supple),74:94-101.
